CPA
ALNY icon

Capital Performance Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Performance Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-541
Closed -$215K – 473
2025
Q4 		$215K Sell
541
-47
-8% -$20.8K 0.02% 406
2025
Q3 		$268K Buy
+588
New +$239K 0.04% 240
2025
Q1 		– Sell
-877
Closed -$206K – 262
2024
Q4 		$206K Buy
877
+437
+99% +$115K 0.07% 149
2024
Q3 		$121K Buy
+440
New +$115K 0.04% 169

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Performance Advisors's ALNY Position: Q1 2026 in Review

Capital Performance Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 541 shares — an estimated $215K sold.

Capital Performance Advisors first reported a position in ALNY in Q3 2024 and held it in 4 quarters. The position peaked at $268K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Capital Performance Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 541 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $215K.
  • Capital Performance Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Capital Performance Advisors's Alnylam Pharmaceuticals position peaked at $268K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capital Performance Advisors's 13F filing for Q1 2026, filed 7 May 2026.